FDA Orphan Drug Status Already Granted for Pancreatic and Bone Cancer
TAMPA, FL, February 04, 2021 /24-7PressRelease/ — Singh Biotechnology’s drug SBT-100 has been shown in vitro to inhibit the growth of breast cancer cells by 93% in three days, prostate cancer cells by 92% in three days, brain cancer cells by 62% in three days, pancreatic cancer cells by 85% in three days and bone cancer cells by 83% in three days. The FDA has already granted SBT-100 Orphan Drug Status for pancreatic cancer and osteosarcoma (bone cancer). The properties of SBT-100, which is a single domain antibody, are so novel that it allows the drug to actually penetrate the cell and inhibit the major switches that cause many cancer cells to grow.
This is the first demonstration of a cell-penetrating single domain antibody giving a therapeutic effect in human cancers. Even more astonishing is that Singh’s SBT 100 is able to penetrate the Blood-Brain Barrier, a phenomenal medical breakthrough that many scientists thought was impossible. All the company’s experiments have been independently conducted by independent contract research organizations. Singh owns 100% of the patents worldwide. The company has raised over five million dollars mostly from oncologists, ophthalmologists, and other physicians. The company is raising money from investors to complete FDA required toxicology studies in order to begin clinical studies. The “Global Oncology Market Forecast” for 2023 is 202.5 billion U.S. dollars.
For more information about Singh Biotechnology’s cancer drug innovations or Dr. Sunanda Singh, please call Ashu Parihar at (610) 996 3142, email firstname.lastname@example.org or Bruce Dobbs (404) 246 7899 email@example.com
Singh Biotechnology (SBT) is a privately held company based in Tampa Bay, Florida.
SBT is pioneering the development of unique therapeutic agents to treat diseases with great unmet need.
We use our in-house, technology platform to engineer first-in-class sdAbs capable of penetrating the cell membrane and crossing the blood-brain barrier.
Our mono-specific and bi-specific antibodies are designed to directly target intracellular proteins central to the pathogenesis of disease.
SBT’s technology platform and therapeutic agents have all been developed internally, and have not been licensed from any third party.
We have patents on our intellectual property.
For the original version of this press release, please visit 24-7PressRelease.com here